

Scott Jones

02 March, 2024

Importance of High-Quality Study Conduct

Our collective goal: successfully develop a new treatment for an indication with an unmet need, while ensuring that each study participant receives the highest level of medical care and attention.

Priovant

- Daily review of each patient's disease progression data (labs, patient and investigator assessments), to flag any patients who may be at risk of worsening disease
- 24/7 availability to assist sites in addressing AEs, AESIs, and SAEs that patients may experience
- 24/7 availability (on-site and virtual support) to assist sites with data entry and study conduct questions/issues

Site

- Proactive identification of patients who may need rescue or be at risk of study discontinuation
- Open communication with sponsor team regarding at-risk patients
- 100% data entry completion within 48-72 hours of every study visit
- Adherence to sponsor-provided study conduct best practices



What we ask of you coming out of this session...

- 1. Your attention and participation to best practices will directly impact the success of this trial and our ability to deliver new therapies to patients with DM
- 2. Accurate and timely data entry is essential
- 3. Ensure patient questionnaires are performed correctly and accurately
 - HAQ, PtGA-VAS
- 4. Perform the TB test correctly
- 5. Use the proper tools for shipping samples
- 6. Make sure that all SUSARs are reviewed, acknowledged, and filed in the ISF



Data Entry

Expectation

- Data entered within 48-72 hours after each study visit (including any medication changes)
- Adverse events and any associated medications/procedures entered within 48 hours
- Timely and routine query closing (within 1 week of queries being raised)

Why it's important

- Priovant Medical and Clinical teams review patient data to identify any patients who are at risk and ensure protocol adherance.
- The faster data is uploaded, the more prepared the sponsor team can be to ensure patient safety.
- The Priovant Clinical Monitoring team is working diligently to make sure that your site is up to date with all documentation, to ease your site's query backlog burden during interim data collection and study closeout activities




- 1. Start with any queries of interest:
 - Safety, Eligibility, Steroid Taper, Rescue, Potential Protocol Deviations
- 2. Queries related to IDMC
- 3. Prioritize all queries aging >60 days
- 4. Work from oldest to newest open queries

If any study team member is spending more <u>than 45 seconds</u> trying to figure out what a query is asking, reach out to your site's CRA for a quick response.



Example of data entry best practices – IDMC queries

- VALOR's Independent Data Monitoring Committee (IDMC) meets every 3 months to review study data and ensure safety of clinical trial participants
- Open data queries related to an upcoming IDMC meeting are critical to close within 48 hours, as the data points in question are being reviewed by the independent committee with heightened attention for patient safety
- Site review of open queries multiple times a week is vital to ensure that these queries are addressed within the required time frames. If you ever have any questions about the query, our CRAs are always happy to help!





Data entry best practices – prioritizing aging queries

- CRAs will routinely send each site a list of open queries organized by date, like this example below.
- Prioritize closing out queries with the **most days unresolved**, first.

				Query			
Folder 🗠	Form 🗠	Field 🖌	Log # 🛛 🗠	Status 🖓	Qry Open Date 🛛 🗠	Query Text ~	Days Unresolved ~1
COMMON	Dermatomyo	CM2ENDAT	6	Answered	08 Jun 2023	As per guidelines, at a minimum, a Year must be provided v	225
SCREENING	CT Scan	SCNDAT	0	Answered	31 Oct 2023	Please verify results are "normal" as EMR report states "Mi	90
COMMON	Prior And Co	CPPRO	3	Answered	02 Nov 2023	Per EMR please confirm if the following should be added: B	90
SCREENING	Physical Exan	PEPERF	0	Answered	02 Nov 2023	Please provide source, no source in subject binder	90
COMMON	Prior and Cor	CPYN	0	Answered	01 Nov 2023	Per EMR please confirm if endometrial ablation should be a	90
SCREENING	Standard 12-	EGRS	0	Answered	01 Nov 2023	Per Banook report, CS Right Bundle Branch Block on ECG. N	84
VISIT 6 (WEE	Health Asses	HAQDIQ4I	0	Answered	01 Nov 2023	Per source with some difficulty	84
VISIT 6 (WEE	Health Asses	HAQDIQ4J	0	Answered	01 Nov 2023	per source without any difficulty	84
VISIT 6 (WEE	Health Asses	HAQDIQ4K	0	Answered	01 Nov 2023	per source with some difficulty	84
SCREENING	Physician Glo	PHGARI	0	Answered	01 Nov 2023	Please have physician date the correction on the source.	84
VISIT 4 (WEE	Patient Globa	PTGIC01	0	Answered	01 Nov 2023	Patient chose both no change and slightly worse on source.	62
COMMON	Drug Accoun	DAVISD	3	Answered	01 Nov 2023	Please add log lines for IP dispensed Aug 17 and Sept 27 ald	56
SCREENING	Physical Exan	PERES	4	Answered	31 Oct 2023	Source not updated. Refer to encounter note dated 24Aug2	49
SCREENING	2017 EULAR/	EUP1PP	12	Open	13 Dec 2023	Was EULAR/ACR Idiopathic Inflammatory Myopathies asse	49
SCREENING	2017 EULAR/	EUP1CTR	11	Open	14 Dec 2023	Please verify if assessed and update on source and in EDC.	48
SCREENING	Myositis Dise	MDATCUDA	0	Answered	14 Dec 2023	Per source and measurement, this is 3.7cm. Please verify a	48
SCREENING	Vital Signs	VSTEMP	0	Answered	15 Dec 2023	Per EMR, temperature is 85 and pulse is 98.9. These appea	47



Data Entry Best Practices – Steroid Taper Entry

As per the earlier sessions at the Investigator Meeting, the steroid taper is a critical component of our study protocol.


BEFORE WEEK 12	WEEK 12	- WEEK 36	WEEK 36 – WEEK 52
Remain on stable baseline dose of prednisone (≤ 20 mg/day or equivalent)	Prednisone should be tapere equivalent). Tapering dose below 5 mg/d investigator's discretion. Stable daily dose at Week 12		Prednisone dose should be stable at ≤ 5 mg/day (or equivalent).
	> 10 and ≤ 20mg	Taper 2.5 mg every 2 weeks to 5 mg/day	
	≤ 10 mg	Taper 2.5 mg every 4 weeks to 5 mg/day	

There are up to 2 eCRF pages relevant to the steroid taper that should be entered within 72 hours of the study visit.

- 1. Corticosteroid Tapering eCRF = This documents whether a reduction in CS occurred at that visit
- 2. DM Concomitant Medication Log = If there was a change in dose, the new dose should be documented here.



Example of Data Entry Best Practices – Steroid Taper Entry



priovant

Example of data entry issues – MDAAT partially-entered





The most commonly missed data points are in the 2017 EULAR Assessment performed at screening, and the MDAAT.

Please ensure all investigator assessments are fully answered before the investigator leaves the room.



EDC – Clinical Worsening CRF

priovo

Upcoming EDC update: CW CRF will only indicate whether the calculations of each criterion meet or does not meet the criteria. If the calculations meet criterion and if a participant requires a single burst of corticosteroids (before Week 12) or a rescue (after Week 12), indicate the change of medication in the Dermatomyositis Prior and Concomitant Medications CRF.

	Prior Visit	This Visit	Derived Message
V3 and V4	NA	Yes	The participant meets clinical worsening at this visit. If needed, a single course of corticosteroids is permitted, and if dosed, the Dermatomyositis Prior and Concomitant Medications eCRF should be completed.
V3 and V4	NA	No	The participant does not meet clinical worsening at this visit.
V5 and beyond	Yes or No	No	The participant does not meet clinical worsening at this visit.
V5 and beyond	Yes	Yes	The participant meets clinical worsening at this visit and the prior visit. If needed, rescue therapy is permitted, and if dosed, the Dermatomyositis Prior and Concomitant Medications eCRF should be completed.
V5 and beyond	No	Yes	The participant meets clinical worsening at this visit but not the prior visit. Rescue therapy is not permitted, please reach out to Medical Monitor.
V5 and beyond	Yes (diff criterion)	Yes (diff criterion)	The participant meets a different clinical worsening criterion at this visit from the prior visit. Rescue therapy is not permitted, please reach out to Medical Monitor.
UNS	N/A	Yes	The participant meets clinical worsening at this visit. Before Visit 5 (Week 12), a single course of corticosteroids is permitted, if needed. After Visit 5 (Week 12), rescue therapy (if needed) is permitted if same clinical worsening criteria is met at two consecutive visits 3 weeks apart. For all rescue medications, complete the Dermatomyositis Prior and Concomitant Medications eCRF.
UNS	N/A	No	The participant does not meet clinical worsening at this visit.
	I		

EDC – Rescue Therapy

Any change in medication, including rescue therapy, should be captured in the Dermatomyositis Prior and Concomitant Medications CRF

Is this a rescue medication during the Blinded Treatment Period? Yes or No

If Yes, you must choose reason for rescue therapy:

- Met clinical worsening criteria
- Did not meet clinical worsening criteria but needed rescue → Specify the reason for the rescue needed in free text. Enter symptoms, lab changes, or specific conditions that warranted a rescue therapy.



Patient Questionnaires

Questionnaire Organization

- Please reference the schedule of activities in the protocol 1 week prior to each study visit to ensure that the correct investigator and patient questionnaires are provided to PIs and participants at each visit.
- If missing documentation:
 - 1. Pull extra questionnaires from the end of the supplementary binder to ensure that all necessary questionnaires are completed
 - 2. Contact your site's CRA to troubleshoot the issue and order additional documentation

Example:

- Subject 10-111-1111 is coming in for V4 next week.
- Upon review of the schedule of activities, 10-111's study coordinator discovers that they are missing the CDASI Investigator Questionnaire in this packet

Solution:

- Pull an extra CDASI questionnaire from the extras located at the end of the supplementary binder and incorporate into the visit packet
- Contact 10-111's monitor to inform of the issue
 - Monitor will ask additional questions to identify if documents are missing from other visits (e.g V6, V8, V10) and will ensure that new questionnaires are shipped to the site.



- 1. On average, it can take approximately 15-20 minutes to complete all PROs
- 2. Please provide the PROs to the patient in the order of the timeframe they need to considering, when answering the questions e.g.:
 - I. PRO tools: PtGA skin, muscle, pain, swallow, flexibility, S (today)
 - II. PtGlobal Disease (<u>today</u>)
 - III. PP-NRS (previous 24 hours)
 - IV. FACIT Fatigue (past <u>7 days</u>)
 - V. HAQ (over the **<u>past week</u>**)
 - VI. PtGI-C (since starting medication)
 - VII. SF-36 (1 year ago and past 4 weeks)

All of the forms for both the Physician and the Patient assessments can be found organized by study weeks in the Supplementary Binder provided to each site

Patient Reported Outcomes – Best Practices

Patient accuracy of the assessments is critical, particularly the Health Assessment Questionnaire (HAQ)

We ask for your support in following some best practices while the patient fills out each PRO to ensure the forms are completed accurately:

- 1. Please remind the patient of the importance of completing these accurately. The patient should be aware of the concept of questionnaire fatigue.
- 2. Please sit with the patient while they complete each questionnaire. They should be provided to the patient one at a time.
- 3. Prior to completing each PRO, read the instructions out loud to the patient to ensure they understand the time point they need to consider for their answers
- 4. Once the PROs are completed, review them with the patient:
 - Have they left any questions blank?
 - Are there any discrepancies?
 - Were there any questions on the form the patient did not understand?
- 5. Confirm that the response reflects how the patient feels, without biasing the patient.
 - Full comprehension of what the questionnaire is measuring, and that pt has answered appropriately



HAQ/Patient Global VAS Divergence

Example 1: Unstable Patient Global VAS, while HAQ disability score stays stable

- Subject 88-777-6666's HAQ Disability Score was reported as a 2.34/3 at V6. This indicates that their disease is causing a significant impact to their daily life in this past week.
- Their Patient Global Activity Visual Analog Scale results were reported as a 1.1/10 at V6, indicating that their disease activity is mild on the day of the visit.
 - What do you observe about the trends below and the data at V6?
 - What actions should you take at each visit to ensure integrity and accuracy of this participant's answers?

Visit	PtGA-VAS	Visit	HAQ
V2	7.2	V2	1.88
V3	4.9	V3	1.00
V4	2.8	V4	1.05
V5	2.7	V5	0.95
V6	1.1	V6	2.34



Issue:

HAQ/Patient Global VAS Divergence

The Health Assessment Questionnaire and Patient Global Activity – VAS are the most important patient-reported outcomes questionnaires for this study, as they directly factor into the study's primary endpoint, the TIS

Resolution:

- In this example, the patient's report of their disability within the past week has gotten worse, while their analysis of their current disease activity burden shows that they are only experiencing mild symptoms.
- After the questionnaires are completed, sit with the patient and review their answers. If any discrepancies are noticed, these can be pointed out as facts, i.e:
 - "Your HAQ score implies that you've seen worsening of your disability this past week, but the PtGA-VAS indicates improvement of your overall disease activity today. Does this reflect how you are feeling today?"
 - If the patient says "yes, this is accurate" great. If they feel that their score is inaccurate base on the clarification of what their answers mean, they can change their scores while they are still in clinic for their visit.

Visit	PtGA-VAS	Visit	HAQ
V2	7.2	V2	1.88
V3	4.9	V3	1.00
V4	2.8	V4	1.05
V5	2.7	V5	0.95
V6	1.1	V6	2.34
V7	0.8	V7	0.88



IRT and IP Best Practices

When randomizing subjects in the IRT, the BASELINE PhGA-VAS score must be entered

remier IRT.	DEMO PVT-2201
ts 🔹 Drug Reconciliation 💌 IP 💌 Reports 💌 Study	y Documents
Random	nization
Subject ID	10-999-1002
Subject DOB	1980
Has the subject met all inclusion and none of the exclusion and is	○ Yes ○ No
Enter the Baseline Physician Global Disease Activity Visual Analog Scale (VAS) Category	\odot 0 to 4.9 cm \odot 5 to 10 cm
Back	Cancel

- At randomization, the IRT prompts the site to enter in the Physician Global Disease Activity Visual Analog Scale (VAS) Category
- This applies to the assessment **at V2**, not at V1
- Prior to randomization, please use the study-provided ruler to measure the investigator's assessment and enter this into the IRT
- This ensures that patients whose disease activity has gotten worse, or improved, since screening are stratified correctly into the study



In-clinic doses: V2, V3, V7, V12 (if participant is rolling over into OLE)



Please contact subjects 1-2 days prior to their upcoming visit



Remind them to hold off on taking their daily IP until arriving in clinic for their scheduled study visit




This ensures accurate records of IP dosage timing for PK sample draws




IP Best Practice – Keep Records of Returned IP Kits

A photocopy of the blister card containing participant dosing record should be filed in the source.

Participants should be instructed to record the date, time and their initials with each dose.





Include the Subject ID when saving the photocopy to the source charts.



Lab Samples

Best Practice: Confirm Lab Kit Supply At Least 2 Weeks Prior to Study Visit

To prepare for every study visit, confirm that you have sufficient, non-expired lab kits and additional supplies to cover all specimen collections

Visit Kits

Please reference Lab Manual Section 1.5 (Laboratory Supplies) at least 2 weeks prior to every study visit to ensure that the necessary kits are:

- 1. On-site
- 2. Not at risk of expiration

Other Supplies

- Validated 2-8°C Nanocooler
- Frozen Aliquot Box
- Thermosafe Coolers with dry ice markings
- Ambient Sample Packaging
- Ambient/Frozen Airbills

If you need any of the above supplies, you can re-order them through ACM: <u>https://labstar.acmgloballab.com</u>. **Note that lab kits may take up to 2-3 weeks to arrive on site**

Even if you don't have the necessary supplies in the 2 weeks prior to any study visit, <u>do not cancel the visit</u>. Reach out to Priovant and we will identify a solution that does not delay the patient's study participation/cause protocol deviations



Correct lab sample processing is critical!

Mistakes lead to delays, repeated patient visits and draws, and more work for you

- 1. Inaccurate labeling of lab samples leads to DIFs and AIs unnecessary work for you
- 2. TB lab processing is the #1 reason for randomization delays and patient burden
- 3. Improper packaging and shipping wastes the patients time and effort, increases burden for patients and site staff, and delays the start of the study for the patient

Be sure the personnel managing lab samples are properly trained

If you have questions about lab samples - call your Priovant (Drew, Sabrina, Scott)



Sample Labelling and Requisitions

Requisition Details

- Complete legibly and accurately
- All samples must include a requisition form within the shipment
- Ensure ALL elements of requisition are complete (e.g. subject age and gender; fasting status [no fasting required for any VALOR lab draws])

Tubes are prelabelled, but subject ID must be written on the label prior to packaging



nvestigator: Subject ID: 2	999 Z9997 Visit : F Sample Investigator 123 Main St York 14624	Kit A: Immunogenicity	GLOB	
				AL LABORATURIES
dat product number	0 0 1 2 999			
	'Dash' 1 digit phase 'Dash' 2 digit site number 'dash	Stie, clease do not include subject initials:		
digit subject number	Date: (DD MMM YYYY)	Gender:	Male	Female
Day Mo	enth Year			
Site: Provide true yes	er of birth only			
Collection De	te: (DD MMM YYYY)	Please Select Visit:		
Collection Da		V1 Immunogenicity (V10		
Day	Month Year	V2 Immunogenicity (V11		
Duy		V3 Immunogenicity (V12		
Blood Collect	tion Time: (use 24 hour clock)	V4 Immunogenicity (V13		
		V5 Immunogenicity (V14		
	· 🖵	V6 Immunogenicity (V15 ET/V7 Immunogenicity (
		Illness Immunogenicity (V9010A)	
		Completed By:	1	
	SEE LABORATORY N	IANUAL FOR DETAILED INSTRU	ICTIONS	FOR UNSCHEDULE VISIT ONLY:Please
Test Name	Collection Instruct		Test Number	indicate required tes
Imm ELISA Prim	(1) 1.8mL cryovial, fr		T4800	
Imm Neut Prim	(1) 1.8mL cryovial, fi		T4901	
Imm Back-1 Imm Back-2	 1.8mL cryovial, fr 1.8mL cryovial, fr 		T4802 T4803	
Imm Back-2	(1) 10mL Sarstedt A		T4803	H
IIIII Dduk-3	(I) TOTAL BAISteur A	aquor.	14004	
Comments:				
Comments:				
Lab Use Only:		Date Received:		NONSPA1
Lab Use Only: Samples FR	Z 1.8mL Serum Cryo (Pri) (2): FI	Date Received: RZ 1.8mL Serum Cryo (BU) (2):		NONSPA1
Lab Use Only: Samples FR		RZ 1.8mL Serum Cryo (BU) (2):		-



QuantiFERON TB Test Processing Best Practices

IMPORTANT: follow the lab manual precisely for collection and handling of QuantiFERON-TB Gold Plus Tests. Ensure the following to prevent collection and testing errors:



All tubes are at room temperature and properly filled with **the blood meniscus falling within the black bar on the label**



All tubes are fully inverted 7 - 10 times after collection (NOTE: do not vigorously shake tubes as that may cause gel disruption) and incubated for 16-24 hours at 37 ± 1 ° C




All tubes are centrifuged at 2,000-3,000 RCF (g) **for 15 minutes.** If the gel plug did not separate from the plasma, re-centrifuge



All tubes are shipped in **approved**, **ACM-provided NanoCoolers or Pelican coolers.** DO NOT SHIP SAMPLES IN PACKAGING OTHER THAN SPECIFIED IN THE LAB MANUAL










Sample Packaging and Shipping – QuantiFERON TB

STEP1	STEP 2	STEP 3	STEP 4
	Ensure the NanoCoollogo has		
Open the package and remove the item with the silver foil. Press straight down on the actuator button with thumb.	turned blue, indicating cooling action has begun. Confirm cooling action by touching the surface.	Place the labelled refrigerated samples in the main compartment of 95 kPa biohazard bag.	Place the completed requisition form into the rear compartment of 95 kPa biohazard bag.
STEP 4	STEP 5	STEP 6	
A REAL PROPERTY OF THE RE			
Remove the tape liner and seal the 95 kPa biohazard bag.	Place the 95kPa biohazard bag into the insulated payload compartment.	Replace the cooler in its original position in the box. Press firmly to ensure a snug fit.	Close the package and insert the flaps. Tape the lid shut in the appropriate locations.




Sample Packaging and Shipping -- Ambient





Sample Packaging and Shipping -- Frozen





Safety Acknowledgements

Best Practices: SUSARs

SUSARs: Suspected Unexpected Serious Adverse Reaction

- Immediately after each site is activated, the study team receives a Safety Gap Pack containing all SUSARs issues since the last IB edition was released
- Throughout the study, sites will be receiving individual safety reports from the sponsor team via email
- When each safety gap pack OR individual safety report is received:
 - 1. Ensure PI reviews and acknowledges receipt of each report via e-mail
 - 2. Print the report and the acknowledgement and file in the ISF




Patient Retention

Planning ahead can help to alleviate the stress of 12 visits over 52 weeks

Proactive scheduling and support for a participant's other commitments can alleviate potential issues

- Some patients struggle with the visit schedule and frequency of visits
 - Every four weeks through V5 (week 12)
 - Every six weeks through V12 (week 52)
- Plan the full 12-visit schedule with the patient before randomization
 - Use VALOR Visit Calculator
 - Discuss which dates work best for the patient within the allowed windows
 - Can adjust the date of randomization by a few days to avoid challenging dates for the patient
 - Utilize the "VALOR Study Schedule and Planner" to write out each visit date on hard copy for each patient.
- Full trial scheduling allows for patients to
 - Visualize their experience in advance
 - Avoid any scheduling issues with holidays, vacations, events
 - Feel in control of their experience

Plan the upcoming year with patients so they can prioritize the trial visits



	Visit	Earliest Appointment Date	Target Appointment Date	Latest Appointment Date
	V3	Friday, March 8, 2024	Monday, March 11, 2024	Thursday, March 14, 2024
	V4	Friday, April 5, 2024	Monday, April 8, 2024	Thursday, April 11, 2024
	V5	Friday, May 3, 2024	Monday, May 6, 2024	Thursday, May 9, 2024
	V6	Friday, June 14, 2024	Monday, June 17, 2024	Thursday, June 20, 2024
	V7	Wednesday, July 24, 2024	Monday, July 29, 2024	Saturday, August 3, 2024
	V8	Wednesday, September 4, 2024	Monday, September 9, 2024	Saturday, September 14, 2024



Supporting patients with travel to the site improves retention

Identify those patients who have mobility issues or travel a long distance for support

- Travel to and from the site can be difficult for some patients
 - Those with mobility issues
 - Those traveling a long distance (in their opinion)
 - Those without caretaker support
- Priovant offers travel support and reimbursement via Elligo/ClinEdge
 - Patients +1 can have travel arrangements made for them or be reimbursed
 - Car service, flights, hotels can be arranged in advance to avoid OOP
 - Meals, mileage can be reimbursed via the RealTime portal



- If you need assistance with Elligo, please contact Scott, Drew (LATAM), Sabrina (US/CAN) for more details
- If you offer your own travel support, please ensure your patients have access

Identify which patients may need travel support and be sure they take advantage of the support



Exercise Regimen

It is vital that patients utilizing physical therapy or an exercise regimen remain on a steady regimen throughout the entire study

At or prior to V1:

- Ask the participant about any exercise or physical therapy regimen at the start of the study
- Document this regimen in the EDC
- Inform the patient that they should maintain this regimen throughout the course of the study
 - Priovant can provide support for maintaining an exercise regimen that starts prior to screening

At each study visit:

- Remind patient to maintain the same exercise regimen that was in place prior to randomization
- Remind patient to avoid strenuous activities outside their normal routine during the week prior to each visit
- Document any changes to exercise regimen if they occur throughout the study



Photography

Photography is an important way to evaluate patients' skin symptoms over time

Photography at study visits:

- 1. Sites should conduct photography in line with their process for photography in the normal clinic setting
 - Camera (smartphone or institutionally-approved camera)
 - File storage (USB, EMR, etc)
 - Patient consent (if separate from your institution's standard ICF)
- 2. If photography is conducted at baseline (V2), photos should be taken at every ensuing study visit
 - Please follow the same lesions or rashes throughout the course of the study from baseline to completion
 - If possible, ensure that the patient is not identifiable in these photos
- 3. Photos should be stored via your institution's approved process; sponsor will collect these photos at the close of the study
- 4. Additionally, sites should print each photo for filing in each subject binder

We strongly encourage your participation and appreciate your support!



